| Literature DB >> 21072231 |
Patrick C Ndimubanzi1, Hélène Carabin, Christine M Budke, Hai Nguyen, Ying-Jun Qian, Elizabeth Rainwater, Mary Dickey, Stephanie Reynolds, Julie A Stoner.
Abstract
BACKGROUND: The objective of this study is to conduct a systematic review of studies reporting the frequency of neurocysticercosis (NCC) worldwide. METHODS/PRINCIPALEntities:
Mesh:
Year: 2010 PMID: 21072231 PMCID: PMC2970544 DOI: 10.1371/journal.pntd.0000870
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Figure 1Life cycle of Taenia solium cysticercosis (source: CDC-DPDx).
Cysticercosis is an infection of both humans and pigs with the larval stages of the parasitic cestode, Taenia solium. This infection is caused by ingestion of eggs shed in the feces of a human tapeworm carrier (1). Pigs and humans become infected by ingesting eggs or gravid proglottids (2), (7). Humans are infected either by ingestion of food contaminated with feces, or by autoinfection. In the latter case, a human infected with adult T. solium can ingest eggs produced by that tapeworm, either through fecal contamination or, possibly, from proglottids carried into the stomach by reverse peristalsis. Once eggs are ingested, oncospheres hatch in the intestine (3), (8) invade the intestinal wall, and migrate to striated muscles, as well as the brain, liver, and other tissues, where they develop into cysticerci (9). In humans, cysts can cause serious sequellae if they localize in the brain, resulting in neurocysticercosis. The parasite life cycle is completed, resulting in human tapeworm infection, when humans ingest undercooked pork containing cysticerci (4). Cysts evaginate and attach to the small intestine by their scolex (5). Adult tapeworms develop, (up to 2 to 7 m in length and produce less than 1000 proglottids, each with approximately 50,000 eggs) and reside in the small intestine for years (6). (This life cycle is available online at URL: http://www.dpd.cdc.gov/dpdx/HTML/Cysticercosis.htm).
Results of search strategies on neurocysticercosis epidemiology published between 1990 and 2008 (June).
| Database | Link | Hits |
|
|
| 0 |
|
|
| 1 |
|
| 1 | |
|
| 4 | |
|
|
| 1 |
|
|
| 0 |
|
|
| 209 |
|
|
| 33 |
|
|
| 0 |
|
|
| 5 |
|
|
| 0 |
|
|
| 0 |
|
|
| 19 |
|
|
| 2 |
|
|
| 1 |
|
|
| 0 |
|
|
| 0 |
|
|
| 0 |
|
|
| 4 |
|
|
| 0 |
|
| 1 | |
|
|
| 240 |
|
|
| 6 |
|
|
| 0 |
|
| 3 | |
|
|
| 0 |
|
|
| 9 |
|
|
| 2 |
|
|
| 34 |
Figure 2Flowchart describing the number of papers remaining at different phases of the study.
Descriptive summary of the studies retained for the quantitative sorted by region.
| Country, year(s) of study | Reference (language) | Design | Source population | Target population | Study population | NCC diagnosis/definition | Definition of seizures/epilepsy | % Active Epilepsy (AE) | Measure of frequency | Sampling |
|
|
| Cross sectional | Autopsies at the School Hospital Uberaba, Minas Gerais | 2218 autopsies | 2218 | Autopsy/presence of cysts at histological or macroscopic examination of the brain | NA* | NA* | Proportion of NCC among all autopsies | Census |
|
|
| Cross sectional | Autopsies at the School Hospital Uberaba, Minas Gerais | 1884 autopsies | 1596 with complete data | Autopsy/not mentioned | NA* | NA* | Proportion of autopsies | Census |
|
|
| Cross sectional | Autopsies at the Hospital das Clinicas da Faculdade de Medicina de Ribieirao Preto-USP | 2522 autopsies | 2522 | Autopsy/presence of cysts at histological or macroscopic examination of the brain | NA* | NA* | Proportion of NCC among all autopsies | Census |
|
|
| Case series | People attending the Imaging Diagnostic Center and the General Hospital of Nova Iguaçu, Rio de Janeiro | 36379 CT scans of patients | 36379 | Brain CT-scan/acute (visualization of cysts at different development levels, but not calcified) or chronic (calcifications or granulomas as described by | NA* | NA* | Proportion among patients with a CT-scan | Census |
|
|
| Case series | People attending the Centro de Tomografia Computadorizada e Ressonância Magnética (CETAC), Curitiba, Paraná | 1000 consecutive CT scans of PWE§ | 1000 | Brain CT-scan/Definite (cystic or racemose lesions), suggestive (focal intraparenchimal calcified lesions) | Clinical diagnosis. Seizures classified according to | NA* | Proportion among PWE who underwent a CT scan of the brain | Census |
|
|
| Cross sectional | 9955 people screened in rural communities, Santa Cruz Department, Cordillera province | 124 PWE§ in community | 105 accepting the CT | Brain CT-scan/Lesions described in | ≥2 unprovoked epileptic seizures occurring >24 hours apart | Not reported | Prevalenceð/ Proportion among PWE§ | Community cluster/Door to door survey |
NA*: Not Applicable; SRS**: Simple RandomSample; PWE§: People with epilepsy; Prevalenceð: Prevalence of NCC associated-epilepsy in the community; AE¶: Active Epilepsy; PWS¥: People With Seizures.
Figure 3Distribution of documents identified during a systematic search of the literature from 1990 to 2008 on the frequency of neurocysticercosis which were included in the three phases of the review.
a) Phase I (n = 565), b) Phase II (n = 290) and c) Phase III (n = 26).
Frequency* of NCC (95% CI) identified in the systematic review.
| Country, year(s) of study | Reference | Measure of frequency | % NCC | 95% CI |
|
|
| Percentage of NCC among autopsies of adults | 2.4 | 1.8–3.0 |
|
|
| Percentage of NCC among autopsies of adults | 2.6 | 1.8–3.4 |
|
|
| Percentage of NCC among autopsies of adults | 1.5 | 1.0–2.0 |
|
|
| Percentage of NCC among autopsies of adults | 1.9 | 1.2–2.8 |
|
|
| Percentage of NCC among people with JE | 19.4 | 14.6–24.8 |
|
|
| Percentage of NCC among people with a brain CT-scan | 0.2 | 0.15–0.24 |
|
|
| Percentage of children (ages 2–14) with partial seizures | 52.0 | 38.5–65.2 |
|
|
| Percentage of children (ages 1–12) with partial motor seizures | 2.0 | 0.4–5.7 |
|
|
| Percentage of children (ages 0–15) with simple partial seizures | 10.1 | 6.3–15.2 |
|
|
| Percentage of people with seizures seen in emergency rooms | 2.1 | 1.5–2.9 |
|
|
| Prevalence among people EITB positive | 23.0 | 14.0–34.2 |
|
|
| Prevalence among people EITB negative age-sex-village matched to EITB+ | 18.9 | 10.7–29.7 |
|
|
| Prevalence among people EITB positive and without epilepsy | 34.0 | 21.5–48.3 |
|
|
| Prevalence among a SRS | 13.8 | 6.1–25.4 |
|
|
| Prevalence among a SRS | 9.1 | 5.1–14.8 |
|
|
| Percentage among a SRS | 14.4 | 8.5–21.2 |
|
|
| Percentage among a age-gender matched (to epilepsy cases) sample of people without epilepsy in a community | 5.2 | 0.1–26.0 |
|
|
| Incidence rate of inpatients with NCC (/105 person-years) | 1.5 | |
| USA, 2002–05 | Thompson, unpublished | Incidence rate of inpatients with NCC (/105 person-years) | 0.29 |
*JE: Japanese encephalitis;
**SRS: Simple random sample;
§: NCC excluded patient with solitary cyst or granuloma in the brain.
Prevalence (%) of NCC-associated epilepsy and 95% Bayesian Credible Interval (95% BCI) in community-based studies.
| Country, year | Reference | Number of people with NCC (number with CT-scans) | Number of people with Epilepsy | Number of people screened for the presence of epilepsy | % NCC-associated epilepsy in the study population (95%BCI) |
| Bolivia, 1994 |
| 29 (105) | 124 | 9955 | 0.35 (0.24–0.49) |
| Ecuador, 1994 |
| 14 (26) | 31 | 2723 | 0.62 (0.36–0.97) |
| Ecuador, 2003 |
| 5 (19) | 23 | 2415 | 0.27 (0.11–0.54) |
| Honduras, 1997 |
| 33 (90) | 100 | 6473 | 0.57 (0.40–0.78) |
| Burkina Faso, 2007 | Carabin; unpublished | 17 (68) | 39 | 888 | 1.32 (0.81–2.05) |
| Urban India, 2003 |
| 35 (101) | 116 | 38105 | 0.11 (0.07–0.15) |
| Rural India, 2003 |
| 11 (61) | 78 | 12512 | 0.12 (0.06–0.20) |
*These studies only included patients with active epilepsy (defined by at least one epileptic seizure in the past 5 years).
Figure 4Forest plots of the proportion of NCC (95% CI) in people with epilepsy from 12 studies reporting from cases in all age groups.
*Indicates studies among people with epilepsy and seizures. ** Indicates studies among people with active epilepsy only.
Figure 5Forest plots of the proportion of NCC (95% CI) among people with epilepsy in children and adults.
a) people aged between 0 and 19 years old and b) aged 20 years old or more. *Indicates studies among people with epilepsy and seizures. ** Indicates studies among people with active epilepsy only.